Marks fifth consecutive year of improvement, ranking in the top 23% of the Manufacture of Pesticides and Other Agrochemical Products industry – including top...
DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The report "Automotive Refinish Coatings Market by Layer (Clearcoat, Basecoat, Primer), Resin Type (Polyurethane, Epoxy, Acrylic, Alkyd),...
DELRAY BEACH, Fla., Aug. 13, 2025 /PRNewswire/ -- The report "Automotive Refinish Coatings Market by Layer (Clearcoat, Basecoat, Primer), Resin Type (Polyurethane, Epoxy, Acrylic, Alkyd),...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new...
VICTORIA, British Columbia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced its financial results for the second quarter of 2025 and provided a business update. All dollar values are in U.S. dollars unless stated otherwise.
GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.
GLP-1 Plus by Advanced BioNutritionals enters the spotlight with a patented dihydroberberine (DHB) formula in 2025, reflecting rising interest in GLP-1 alternatives and non-injection hunger support solutions.
Science-Backed Supplement Recognized for Advancing Pet Gut and Immune Wellness
PALMYRA, Wis., Aug. 8, 2025 /PRNewswire/ -- Spirited Paw®, a pet wellness brand from...
BANGALORE, India, Aug. 7, 2025 /PRNewswire/ --
What is the Market Size of Chain Transfer Agents Market?
The global market for Chain Transfer Agents was valued...